Rigel Pharmaceuticals announced on May 22, 2025, seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. These presentations will feature data for GAVRETO and REZLIDHIA.
The presentations will include final efficacy and safety data from the Phase 1/2 ARROW study of GAVRETO (pralsetinib) in patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors. This data continues to demonstrate GAVRETO's clinically meaningful and durable responses.
Additionally, collective data on REZLIDHIA (olutasidenib) will be presented, supporting its duration of response and potential clinical benefit. This includes its use in earlier lines of treatment for relapsed or refractory acute myeloid leukemia (AML) patients and in primary refractory patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.